Endocrinology Search
Endocrinology Endocrinology
hypophosphatemia%20-and-%20hyperphosphatemia
HYPOPHOSPHATEMIA & HYPERPHOSPHATEMIA

Hypophosphatemia is an electrolyte imbalance where there is a decrease in the serum phosphate level that is less than the normal range.

It is recognized most often in critically-ill patients, decompensated diabetics, alcoholics or other malnourished persons, and acute infectious or pulmonary disorders.

It may be transient and reflect intracellular shift with minimal clinical consequences.

Hyperphosphatemia is an electrolyte disturbance in which an increase in the serum phosphate level of more than the normal range is present.

Most symptoms of acute hyperphosphatemia are due to secondary hypocalcemia.

The significant level of hyperphosphatemia in adults is >6 mg/dL.

Monitoring

Monitoring of Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients
  • Monitoring of serum phosphate in CKD patients should start in patients w/ grade 3 CKD
    • Frequency of monitoring will be based on the presence & magnitude of abnormalities & the rate of progression of the disease
  • Monitoring of serum phosphate intervals may be as followed:
    • Every 6-12 months in patients w/ grade 3 CKD
    • Every 3-6 months in patients w/ grade 4 CKD
    • Every 1-3 months in patients w/ grade 5 CKD
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Weight loss could sustain T2D remission for 2 years
Roshini Claire Anthony, 08 Apr 2019

About one-third of individuals who achieved remission of type 2 diabetes (T2D) after losing weight with an intensive weight management programme sustained their remission at 2 years, according to long-term results of the DiRECT* trial.

Improved antilipolytic effect in adipose tissue via SGLT2i attenuates weight loss in T2D patients
14 Aug 2019
Progressive lipolysis may be reduced via the improved antilipolytic effect in adipose tissue, which leads to a reduction in future weight loss caused by sodium-glucose cotransporter 2 inhibitors (SGLT2is) in patients with type 2 diabetes (T2D), suggests a recent study.
Maternal prepregnancy obesity implicated in precocious puberty in offspring
06 Aug 2019
Maternal prepregnancy obesity is associated with earlier age at voice break, pubic hair development, axillary hair and acne in sons, as well as with earlier age at menarche, breast development, pubic hair development, axillary hair and acne in daughters, a study has found. These associations appear to be mediated by higher childhood body mass index in sons and partly so in daughters.